The scientist’s investigation covers issues in Internal medicine, Endocrinology, Renin–angiotensin system, Blood pressure and Angiotensin II. His Internal medicine study combines topics in areas such as Placebo and Cardiology. The concepts of his Endocrinology study are interwoven with issues in Pharmacology and Enzyme inhibitor.
His Renin–angiotensin system research includes themes of Angiotensin-converting enzyme, ACE inhibitor, Kidney and Captopril. The study incorporates disciplines such as General practice, Cohort and Urology in addition to Blood pressure. While the research belongs to areas of Heart failure, Joël Ménard spends his time largely on the problem of Myocardial infarction, intersecting his research to questions surrounding Vascular disease, Stroke, Diabetes mellitus, Perindopril/indapamide and Aspirin.
His primary scientific interests are in Internal medicine, Endocrinology, Renin–angiotensin system, Blood pressure and Plasma renin activity. His work deals with themes such as Pharmacology and Cardiology, which intersect with Internal medicine. His studies link Hemodynamics with Endocrinology.
He combines subjects such as Radioimmunoassay, Biochemistry, Enzyme, Angiotensin II and Kidney with his study of Renin–angiotensin system. The various areas that Joël Ménard examines in his Blood pressure study include Anesthesia, Placebo, Surgery and Urology. His research on Plasma renin activity frequently connects to adjacent areas such as Acebutolol.
His primary areas of study are Internal medicine, Endocrinology, Blood pressure, Renin–angiotensin system and Plasma renin activity. His studies deal with areas such as Placebo and Cardiology as well as Internal medicine. His study looks at the relationship between Placebo and fields such as Myocardial infarction, as well as how they intersect with chemical problems.
His Blood pressure research is multidisciplinary, incorporating elements of Copeptin, Vasopressin, Randomized controlled trial and Pediatrics. His study in Renin–angiotensin system is interdisciplinary in nature, drawing from both Angiotensin II, Computational biology, Pharmacology and Protein chemistry. His Plasma renin activity research is multidisciplinary, relying on both Kidney and Renin inhibitor.
Internal medicine, Endocrinology, Aldosterone, Plasma renin activity and Aldosterone synthase are his primary areas of study. His study ties his expertise on Placebo together with the subject of Internal medicine. His Plasma renin activity research is included under the broader classification of Renin–angiotensin system.
His Renin–angiotensin system study combines topics from a wide range of disciplines, such as Angiotensin II and Pharmacology. His Mineralocorticoid study frequently links to related topics such as Blood pressure. His studies in Blood pressure integrate themes in fields like Hazard ratio, Framingham Risk Score, Randomized controlled trial and Urology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson;Alberto Zanchetti;S George Carruthers;Björn Dahlöf.
The Lancet (1998)
Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine
Gordon Guyatt;John Cairns;David Churchill;Deborah Cook.
Cardiovascular Prognosis of Masked Hypertension Detected by Blood Pressure Self-measurement in Elderly Treated Hypertensive Patients
Guillaume Bobrie;Gilles Chatellier;Nathalie Genes;Pierre Clerson.
Clearance systems in the brain—implications for Alzheimer disease
Jenna M. Tarasoff-Conway;Roxana O. Carare;Ricardo S. Osorio;Lidia Glodzik.
Nature Reviews Neurology (2015)
Measurement of Renin Activity, Concentration and Substrate in Rat Plasma by Radioimmunoassay of Angiotensin I
J. Menard;K. J. Catt.
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
M. Marre;G. Chatellier;H. Leblanc;Tam Than Guyene.
Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
M Azizi;A Rousseau;E Ezan;T T Guyene.
Journal of Clinical Investigation (1996)
Masked hypertension: a systematic review.
Guillaume Bobrie;Pierre Clerson;Joël Ménard;Nicolas Postel-Vinay.
Journal of Hypertension (2008)
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)
Michel Marre;Michel Lievre;Gilles Chatellier;Johannes F E Mann.
1993 Guidelines for the management of mild hypertension: MEMORANDUM from a World Health Organization/International Society of Hypertension meeting
Alberto Zanchetti;John Chalmers;Kikuo Arakawa;Ivan Gyarfas.
Journal of Hypertension (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: